Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

Bringing the NHS into the 21st century

As the NHS celebrates its 70th birthday and a £20bn “birthday gift” from the UK government, we find out how one company is delivering what the National Health Service really...

Blue Latitude Health

- PMLiVE

Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?

The next generation of relationship holders will offer highly personalised services

- PMLiVE

Daily Brief: GSK unveils R&D plan, Keytruda OK’d for lymphoma by NICE

News from pharma, biotech and healthcare

- PMLiVE

Happy 70th birthday NHS: the next 70 need to be very different

The UK’s NHS is loved by the British public, while social care is under appreciated and underfunded. The new health secretary is being urged to remedy this to create a...

Celgene building

Celgene’s Revlimid gets a win in late-stage lymphoma

Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates

- PMLiVE

Love Island ads fuel body image problems, warn health leaders

Calls for watchdog to regulate cosmetic surgery adverts

- PMLiVE

NHS England to Vertex: come clean on Orkambi offer

Vertex has offered Orkambi at an almost 90% discount to the NHS, according to BioCentury

Roche Basel Switzerland

Roche’s Tamiflu successor hits the mark in complicated flu

Baloxavir marboxil met its primary objective and cut flu-related complications

- PMLiVE

Daily Brief: Novartis exits anti-infectives drive, Hancock takes over from Hunt and Trump attacks ‘soft Brexit’ plan

The latest from pharma, biotech and healthcare

Roche Basel Switzerland

Roche keeps Venclexta train rolling with new leukaemia filing

The drug could treat AML patients who are ineligible for chemotherapy

- PMLiVE

NHS England says yes to Roche’s Hemlibra

But stalls on funding for Actelion's Uptravi

- PMLiVE

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

A round-up from pharma, biotech and healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links